Fuyuki 亀谷

Dr. Fuyuki 亀谷

Tokyo Metropolitan Institute of Medical Science
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
YSYang Shi
Yang Shi
WZWenjuan Zhang
Wenjuan Zhang
YYYang Yang
Yang Yang
AMAlexey G. Murzin
Alexey G. Murzin
BFBenjamin Falcon
Benjamin Falcon
SSSjors H. W. Scheres
Sjors H. W. Scheres

27 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MSManuel Schweighauser
Manuel Schweighauser
YSYang Shi
Yang Shi
ATAiri Tarutani
Airi Tarutani
F亀Fuyuki 亀谷
Fuyuki 亀谷
AMAlexey G. Murzin
Alexey G. Murzin
MGMichel Goedert
Michel Goedert

30 January 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
F亀Fuyuki 亀谷
Fuyuki 亀谷
MHMasato Hasegawa
Masato Hasegawa
The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or fibrillar amyloid β (Aβ) peptide is the primary cause of Alzheimer's disease (AD), has been the mainstream concept underlying AD research for over 20 years. However, all attempts to develop Aβ-targeting drugs to treat AD have ended in failure. Here, we review recent findings indicating that the main factor underlying the development and progression of AD is tau, not Aβ, and we describe the deficiencies of the amyloid hypothesis that have supported the emergence of this idea.

10 June 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MHMasato Hasegawa
Masato Hasegawa
TATetsuaki Arai
Tetsuaki Arai
TNTakashi Nonaka
Takashi Nonaka
F亀Fuyuki 亀谷
Fuyuki 亀谷
MYMari Yoshida
Mari Yoshida
HAHaruhiko Akiyama
Haruhiko Akiyama

8 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
DADiana Arseni
Diana Arseni
MHMasato Hasegawa
Masato Hasegawa
AMAlexey G. Murzin
Alexey G. Murzin
F亀Fuyuki 亀谷
Fuyuki 亀谷
MAMakoto Arai
Makoto Arai
BRBenjamin Ryskeldi-Falcon
Benjamin Ryskeldi-Falcon

10 June 2009 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TNTakashi Nonaka
Takashi Nonaka
F亀Fuyuki 亀谷
Fuyuki 亀谷
TATetsuaki Arai
Tetsuaki Arai
HAHaruhiko Akiyama
Haruhiko Akiyama
MHMasato Hasegawa
Masato Hasegawa
TAR DNA binding protein of 43 kDa (TDP-43) is a major component of the ubiquitin-positive inclusions found in the brain of patients with frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Here, we report that expression of TDP-43 C-terminal fragments as green fluorescent protein (GFP) fusions in SH-SY5Y cells results in the formation of abnormally phosphorylated and ubiquitinated inclusions that are similar to those found in FTLD-U and ALS. Co-expression of DsRed-tagged full-length TDP-43 with GFP-tagged C-terminal fragments of TDP-43 causes formation of cytoplasmic inclusions positive for both GFP and DsRed. Cells with GFP and DsRed positive inclusions lack normal nuclear staining for endogenous TDP-43. These results suggest that GFP-tagged C-terminal fragments of TDP-43 are bound not only to transfected DsRed-full-length TDP-43 but also to endogenous TDP-43. Endogenous TDP-43 may be recruited to cytoplasmic aggregates of TDP-43 C-terminal fragments, which results in the failure of its nuclear localization and function. Interestingly, expression of GFP-tagged TDP-43 C-terminal fragments harboring pathogenic mutations that cause ALS significantly enhances the formation of inclusions. We also identified cleavage sites of TDP-43 C-terminal fragments deposited in the FTLD-U brains using mass spectrometric analyses. We propose that generation and aggregation of phosphorylated C-terminal fragments of TDP-43 play a primary role in the formation of inclusions and resultant loss of normal TDP-43 localization, leading to neuronal degeneration in TDP-43 proteinopathy.